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Severe Myocardial Dysfunction During Extracorporeal 
Membrane Oxygenation 
By Ronald B. Hirschl, Kurt F. Heiss, and Robert H. Bartlett 
Ann Arbor, Michigan 
l Of the 102 neonates with respiratory failure supported 
with extracorporeal membrane oxygenation (ECMO) at this 
institution between 1984 and 1987, 8 patients developed 
severe myocardial dysfunction that was noted shortly after 
onset of bypass. The neonates in the cardiac dysfunction 
group were more hypoxic (average PaO, = 28 t 8 mm Hg v 
41 k 19 mm Hg, P < .Ol) in the immediate pre-ECMO period. 
Seventy-five percent were unstable hemodynamically (8 
hypotensive, 3 bradycardic, 2 sustained cardiac arrest, 4 
required epinephrine pressor support). On ECMO. 5 of the 8 
neonates developed an ischemic cardiomyopathy that lasted 
for less than 24 hours and resolved without therapeutic 
intervention. In the other 3 cases, prolonged periods of 
dysfunction were noted and afterload reduction through 
administration of tolazoline or hydralazine was beneficial. 
These 8 patients serve to demonstrate the reversible nature 
of postischemic cardiac dysfunction in patients on ECMO and 
in the neonatal population in general. 
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ROLONGED extracorporeal membrane oxygen- 
ation (ECMO) support is now a standard treat- 
ment of respiratory failure in the full-term neonate.‘,2 
At last report, 715 neonatal ECMO cases had been 
performed with an overall survival of greater than 
80%.3 At the University of Michigan we provided 
ECMO support to 102 neonates with severe respira- 
tory failure between 1984 and 1987. In 8 of these 
cases, severe cardiac dysfunction was noted to be 
present shortly after onset of bypass. Cardiac electri- 
cal activity remained normal, but there was a marked 
decrease in pulse pressure and a concomitant de- 
crease in cardiac contractility. Over a period of hours 
to days this cardiac dysfunction resolved. The pur- 
pose of this article is to discuss the phenomenon of 
reversible, postischemic “myocardial stun” in the 
neonate on ECMO and to suggest treatment options.4 
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MATERIALS AND METHODS 
Of the 102 neonates with respiratory failure who have been 
supported with ECMO between 1984 and 1987 at the University of 
Michigan, 8 developed severe left ventricular dysfunction during 
their ECMO course and were retrospectively identified and evalu- 
ated. The first manifestation of cardiac dysfunction on ECMO was 
a flat arterial line waveform. There was no change in monitored 
cardiac electrical activity. The possible differential diagnoses of 
cardiac tamponade and tension pneumothorax were ruled out with 
chest x-ray and echocardiogram. Patency of the umbilical arterial 
line was established and the line even replaced in one case. That 
the patient could be hypovolemic and/or on inadvertent total 
bypass was considered in the differential diagnosis of a loss of 
pulsatile flow. On total bypass, almost all the venous return is 
diverted into the extracorporeal circuit. The patient is then 
exclusively dependent on nonpulsatile extracorporeal flow for 
perfusion. Hypovolemia produces a similar clinical picture because 
less volume is available for cardiac output and the majority of the 
venous return is diverted into the nonpulsatile extracorporeal 
circuit. Evaluation for hypovolemia or an inadvertent total bypass 
situation was performed by the following maneuvers: (1) the 
extracorporeal flow rate was decreased, which should have resulted 
in improvement in the pulse pressure as cardiac output increased; 
(2) the extracorporeal flow rate was increased, upon which the 
ECMO servoregulation should have stopped the pump due to 
insufficient venous return for the increased flow rate; and (3) 
volume challenges of up to 50 mL of albumin or blood products 
(approximately 15 mL/kg) were administered, which should have 
resulted in an improvement in pulse pressure. None of the 
expected responses was elicited and hypovolemia or a total bypass 
situation was excluded. Figure 1 demonstrates the cardiopulmo- 
nary profile of one child with these typical findings. The SvOz was 
measured in the premembrane oxygenator ECMO circuit and was 
67% after stabilization on bypass 2 hours into the ECMO course. 
At that time the ECMO flow rate was 350 mL/min and the pulse 
pressure was 0. With a decrease in ECMO flow rate to 2.50 
mL/min, the pulse pressure did not increase, which would be the 
expected response if the initial decreased pulse pressure were 
secondary to achieving total bypass. Additionally, the SvO, dropped 
to 46% because of the dependence of this patient on ECMO for 
cardiopulmonary support. Meanwhile, the PaO, remained elevated 
in the 176 to 529 range because the source of almost all blood flow 
was the extracorporeal circuit. The ECMO circuit delivers blood 
with PaO, values in the 500 range. Therefore, in this situation, 
because the PaOz will remain elevated whether oxygen delivery is 
adequate or not, the SvO, instead of the PaO, must be followed in 
guiding requirements for ECMO flow. With increase in ECMO 
flow back up to 300 mL/min, note the increase in the SvO, to 63% 
and then to 75% on a flow of 350 mlimin. 
RESULTS 
Descriptive statistics for these eight patients are 
presented in Table 1. Primary diagnoses in these 
eight patients included meconium aspiration syn- 
drome (3) congenital diaphragmatic hernia (3), per- 
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Fig 1. Cardiopulmonary profile of one child with cardiac dysfunc- 
tion while on ECMO. 
&tent fetal circulation (1) and ~-Streptococcus sepsis 
(1). The average gestational age was 39 + 2 weeks 
and the average birth weight 3.26 f .62 kg. The 
average age at the time of institution of ECMO was 
54 5 53 hours and the duration of the ECMO course 
was 123 2 45 hours. Data on the severity of the 
pre-ECMO cardiopulmonary insufficiency found in 
these patients is demonstrated in Table 1. The oxygen 
index (01) is calculated based on the following 
formula: 
F,O, x Mean Airway Pressure x 100 
PaO, 
This numerical value relates the F,O, and postductal 
oxygenation to the level of ventilator pressures re- 
quired to adequately ventilate the neonate. A retro- 
spective analysis in this neonatal intensive care unit 
suggests that an 01 greater than 40 based on three of 
five postductal arterial blood gases each drawn 30 
minutes to 1 hour apart defines the neonate with 
greater than an 80% mortality.’ The last 3 oxygen 
indexes before onset of ECMO for each of the eight 
newborns were averaged and, in chronological order, 
were 51, 71, 74. The average PO, was 26 + 8 mm Hg. 
Six of the newborns were hypotensive, 3 were brady- 
cardic, and 2 sustained cardiac arrest in the immedi- 
ate pre-ECMO period. Four were hemodynamically 
compromised enough to require epinephrine support 
and all received dopamine and/or dobutamine, 6 for 
systemic hypotension and 2 in an attempt to increase 
systemic arterial pressures relative to pulmonary 
arterial pressures in order to decrease transpulmonic 
shunting. 
Once these newborns were placed on ECMO, a 
decrease in pulse pressure to < 10 mm Hg was first 
noted at an average of 2.5 hours into the ECMO 
course and lasted for an average duration of 40 hours. 
A pulse pressure of <5 mm Hg was noted at an 
average of 6.4 hours into the ECMO course, and the 
pulse pressure remained < 5 mm Hg for an average of 
12.2 hours. 
Figure 2 demonstrates the pulse pressure and 
ECMO flow rate with time on ECMO in a child with a 
diaphragmatic hernia who was hypotensive, hypoxic, 
and on an epinephrine intravenous drip before onset 
of bypass support. Pulse pressure remained consis- 
tently in the 0 to 10 mm Hg range for the first 68 
hours. Attempts at improving myocardial contractility 
with dopamine had no evident effect on cardiac 
contractility. After 62 hours on ECMO, afterload 
reduction was attempted with intermittent intrave- 
nous hydralazine administration and a continuous 
amrinone intravenous drip. Shortly after onset of 
administration of these agents the pulse pressure 
improved and the neonate was weaned from bypass 
support without further need for pressor administra- 
tion or afterload reduction. 
Figure 3 depicts the course of a newborn with 
meconium aspiration syndrome placed on ECMO at 
41 hours of age. Immediately prior to institution of 
bypass support, the neonate was profoundly hypoxic, 
hypotensive, and bradycardic requiring cardiopulmo- 
nary resuscitation and extensive pressor support. 
Pulse pressure diminished almost immediately after 
onset of ECMO support, resolving spontaneously 
approximately 20 hours into the ECMO course. The 
child did well subsequently without any evidence of 
cardiac sequelae. 
A slightly different course is demonstrated in Fig 4. 
A neonate with P-Streptococcus sepsis and respiratory 
failure was placed on bypass at 7 days of age. 
Profoundly hypoxic and on dopamine in the immedi- 
ate pre-ECMO period, this newborn had a moderate 
drop in pulse pressure to the 8 to 15 range until 
intravenous dopamine therapy was instituted at 34 
hours into the ECMO course. Pulse pressure further 
decreased to minimal levels despite discontinuation 
of the dopamine. Afterload reduction therapy with 
tolazoline and hydralazine at approximately 140 hours 
on ECMO resulted in marked improvement in pulse 
pressure. Neither nitroprusside nor amrinone ap- 
peared to have any beneficial effect and dopamine, 
early in the course, appeared to actually lead to 
further deterioration in pulse pressure. Afterload 
reduction was continued by intermittent administra- 
tion of intravenous hydralazine for the duration of 
the ECMO course. The child was subsequently weaned 
off bypass. 
Overall, 3 of the 8 children had prolonged (> 24 
hours) periods of cardiac dysfunction (Table 1). In 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig 2. Pump flow rate and pulse pressure with time. A response to 
afterload reduction with hydralazine (hyd) and amrinone (am) admin- 
istration was noted. Dop, dopamine; ca, calcium. 
hydralazine directly resulted in an improvement in 
pulse pressure. Cardiac dysfunction lasted for less 
than 24 hours in the other 5 children (range, 5 to 19 
hours; average, 11.8 2 5.1 hours). These newborns 
appeared to have return of cardiac function spontane- 
ously and unrelated to any of the pharmacological 
agents administered. 
Echocardiographic evaluation was performed in 6 
of the 8 newborns at three points in their course: (1) 
before institution of ECMO; (2) during periods of 
cardiac dysfunction while on ECMO; and (3) after 
resolution of the cardiac dysfunction. Normal to 
slightly decreased left ventricular function (LVF) was 
evident in all children before onset of ECMO sup- 
port. In all cases, when the pulse pressure was 
minimal, LVF was almost always severely or globally 
decreased. Follow-up evaluation demonstrated subse- 
quent normal LVF in all but one child. This child had 
fair LVF, an improvement from the global severe 
decrease in LVF noted during the period of minimal 
pulse pressure. 
“t 100 200 
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Fig 3. Pump flow rate and pulse pressure with time on ECMO. 
Cardiac dysfunction resolved without specific therapy after 8 hours. 
Ca, calcium. 
51 
Fig 4. Pump flow rate and pulse pressure with time on ECMO. 
Pulse pressure appeared to decrease with dopamine (dop) and did not 
improve with hydralazine or amrinone (am) administration. Pulse 
pressure markedly improved with administration of tolazoline (toll 
and nitroprusside (nit). Ca, calcium. 
Electrolyte concentrations were normal with the 
exception of hypocalcemia (8.1 mEq/L) associated 
with hypoalbuminemia (2.9 g/dL). The average creat- 
inine at the start, as well as the creatinine and blood 
urea nitrogen (BUN) at the end of the ECMO course 
was elevated above the normal for the neonate 
population. However, none of the neonates devel- 
oped oliguric renal failure. The creatinine phosphoki- 
nase with isoenzymes was evaluated in one child and 
was normal. Electrocardiography was performed in 
two children during periods of cardiac dysfunction. 
Both were normal. 
Four of these 8 neonates had neurological sequelae 
that resulted in developmental delays and/or sei- 
zures. The other 4 were normal without any evidence 
of neurological or cardiac dysfunction. 
DISCUSSION 
The phenomenon of reversible ischemic cardiac 
dysfunction in neonates was noted in 1961 when 
Burnard and James recognized an association be- 
tween birth asphyxia and subsequent radiographic 
and hemodynamic evidence of ventricular dilatation 
and myocardial dysfunction.’ Although 60% of these 
neonates died, the remainder survived with resolu- 
tion of the cardiomyopathy. Transient cardiac dysfunc- 
tion was also documented by Rowe and Hoffman in 
1972, when they observed three newborns with onset 
of cyanosis and congestive heart failure in the first 24 
hours of life.6 This cardiomyopathy resolved spontane- 
ously between the second and fifth days of life and no 
cardiac sequelae were noted. Reversible cardiac dys- 
function on prolonged cardiopulmonary bypass has 
been described in only one neonate to date.’ As with 
most of the neonates in the present study, the infant 
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was profoundly hypotensive and hypoxic with a PaO, 
of approximately 20 mm Hg in the immediate pre- 
ECMO period. Global dyskinesia of the ventricle 
developed after onset of bypass, which resolved over 
the ensuing 6 days. 
Under normal circumstances, an infant on ECMO 
has adequate cardiac function to maintain at least a 
> 10 mm Hg pulse pressure unless (1) cardiac tampon- 
ade or tension pneumothorax occur, or (2) flow rates 
approach those of total cardiopulmonary bypass. The 
former were ruled out in these newborns by echocar- 
diogram and chest x-ray and the latter through 
attempts at decreasing ECMO flow rate and fluid 
administration, which were not accompanied by the 
usual increase in native cardiac output and pulse 
pressure. In addition, the findings of myocardial 
dyskinesia noted on the echocardiogram of these 
newborns was different than the empty, but contract- 
ing, myocardium of other neonates studied while on 
total bypass. Therefore, it became evident that the 
primary problem was one of cardiac dysfunction after 
onset of bypass support. 
This same group of children was at high risk for 
pre-ECMO cardiac hypoxia and ischemia. The aver- 
age PaO, immediately before onset of ECMO sup- 
port was 26, dramatically more hypoxic than the 
average PaO, of 42 in the 715 neonatal ECMO cases 
reported to date and strikingly similar to the mean of 
24 mm Hg identified by Finley et al” in a report on 
seven newborns with reversible ischemic cardiomyop- 
athy.’ Additionally, 75% of the neonates had episodes 
of hypotension with or without bradycardia, all were 
receiving infusions of dopamine and/or dobutamine, 
50% required cardiovascular support with epineph- 
rine, and 25% underwent cardiac arrest in the imme- 
diate pre-ECMO period. The average 01 was almost 
double the value that identifies the 80% mortality 
group in this nursery. Overall, this describes a group 
of newborns who were much more hypoxic and 
compromised from a cardiovascular point of view 
than the average ECMO child. Indeed, 50% of these 
children had signs of renal insufficiency (elevations in 
both the BUN and creatinine at conclusion of the 
ECMO course) and 50% of these newborns demon- 
strated neurological deficits in their follow-up. In 
routine ECMO cases, the incidence of insufficiency/ 
deficits in these organ systems is only 10% and 20% to 
30%, respectively.” At least 75% of these newborns 
demonstrated clear signs of pre-ECMO cardiac dys- 
function, and, apparently, other organ systems were 
affected as well. 
Once on bypass support, cardiac dysfunction per- 
sisted even though adequate myocardial oxygen sup- 
ply was reestablished. The primary problem was one 
of persistent myocardial dysfunction possibly exacer- 
bated by (1) the increased afterload presented to the 
heart by the ECMO perfusion, and/or (2) preload 
reduction during venoarterial bypass.’ In all in- 
stances, the dysfunction was self-limiting, lasting in 
the range of hours to days and usually resolving 
without specific therapy. Myocardial afterload reduc- 
tion with hydralazine or tolazoline in three prolonged 
cases did appear to be beneficial. 
The reversible nature of some forms of cardiac 
dysfunction after cardiac operation has been demon- 
strated in adults and children supported with ECMO 
or with ventricular-assist devices.‘0-‘3 Approximately 
50% of these patients, mostly in the pediatric age 
group, demonstrated improvement in cardiac func- 
tion over a period of days.13 It is likely that intraoper- 
ative myocardial ischemia is the basis for this revers- 
ible postoperative cardiac dysfunction. In 1982, 
Braunwald and Kloner promoted the concept of the 
“stunned myocardium,” which described the postis- 
chemic heart with prolonged but transient and revers- 
ible dysfunction.4 Studies of acute canine coronary 
occlusion for periods up to 15 minutes were not 
associated with myocardial infarction, but resulted in 
transient dysfunction of the ischemic myocardium for 
several days.14 Myocardial adenosine triphosphate 
(ATP) concentrations have been shown to remain 
reduced and ultrastructural abnormalities observed 
in these myocardial cells for up to 3 days following 
reperfusion.” These findings, along with ventricular 
function, resolved by 7 days. It appears that the 
ischemic myocardium may be stunned and remain 
transiently dysfunctional for a period of days until 
myocardial intracellular ATP levels are repleted.lh 
This phenomenon has been documented in adults 
after coronary occlusion and early reperfusion with 
thrombolysis or revascularization.‘7-19 Resolution of 
myocardial dysfunction over a period of days has also 
been demonstrated after coronary vasospasm in the 
adult.20 As mentioned previously, transient reversible 
myocardial dysfunction of the newborn has been 
documented.s.x 
Presented here are eight neonates who developed 
similar transient, reversible episodes of myocardial 
dysfunction after periods of exposure to profound 
levels of total-body hypoxia and/or hypoperfusion. 
The decreased contractility appeared to be global in 
nature, which is typical for ischemia-induced dysfunc- 
tion in the neonatal heart.” Serial creatinine phos- 
phokinase in one newborn and electrocardiographic 
evaluation in two did not show any evidence of 
myocardial infarction or ischemia. This is consistent 
with the findings in some patients with myocardial 
stun, although numerous cases of reversible dysfunc- 
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tion have been accompanied by transient Q waves tion that myocardial contractility will improve over 
and flattened T waves suggestive of ischemia.h~8~1x*2” the ensuing 24 hours. After that time period, trials of 
With ECMO support, the cardiac dysfunction in this afterload reduction with hydralazine or tolazoline 
study resolved in all eight neonates. Most resolved may be beneficial. 
without any specific therapy over the ensuing 24 Overall, these eight patients, along with the success- 
hours. Those neonates with evidence of cardiac ful postcardiac procedure ECMO cases mentioned 
dysfunction for longer periods demonstrated improve- previously, serve to highlight the potentially revers- 
ment with systemic afterload reduction. Therefore, ible nature of postoperative or postischemic cardiac 
the patient with postischemic cardiac dysfunction on dysfunction, especially in the neonatal and pediatric 
ECMO should be initially watched with the expecta- population. 
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